Therefore, ProCT may reasonably be considered as a complementary marker in patients with thyroid nodules and positive calcitonin results (as a rule-out test) and in MTC patients with unclear postoperative calcitonin trends. This evidence concerns the gene CALCA and medullary thyroid gland carcinoma.